Cencora, Inc. (COR): Results of Operations and Financial Condition
Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q32026.htm EX-99.1 Document Exhibit 99.1 CENCORA REPORTS FISCAL 2026 THIRD QUARTER RESULTS Revenue of $84.8 billion for the Third Quarter, a 5.1 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.94 and Adjusted Diluted EPS of $4.48 Adjusted
How this was made
The 30-second read
Why it matters
Traders can reprice COR’s fiscal 2026 earnings expectations based on the raised adjusted EPS guidance range and the disclosed drivers of revenue growth, margin changes, and acquisition-related cost and financing impacts.
Market read
The filing provides a fresh earnings datapoint (Q3) plus a concrete guidance increase for fiscal 2026 adjusted diluted EPS, which can drive immediate revisions to consensus estimates.
What to watch
Gross profit margin was pressured by increased GLP-1 sales with lower gross profit margins, and operating expenses rose sharply due to OneOncology, which could cap upside if trends reverse.
Background
This is an SEC Form 8-K reporting Cencora’s fiscal 2026 third-quarter results and an update to fiscal 2026 adjusted diluted EPS guidance.
Ticker impact
Cencora reported fiscal 2026 Q3 revenue of $84.8B and raised adjusted EPS guidance to $17.75 to $17.95.
Likely near-term positive bias as guidance is raised, with follow-through dependent on whether margin pressure from GLP-1 mix and acquisition-related costs moderates.
The filing discloses both the quarterly print (revenue, GAAP and adjusted EPS) and a specific guidance range increase for fiscal 2026 adjusted diluted EPS, which are direct drivers for earnings expectations.
Market effects
Signals continued strength in pharmaceutical distribution and healthcare solutions demand, with guidance lift reinforcing confidence in specialty and digital transformation execution.
No explicit regional macro impact beyond disclosed U.S. and international segment revenue growth.
International segment growth and acquisition integration are relevant for global healthcare supply chain sentiment, but the disclosure is company-specific.
Counterpoint
The guidance raise may be partially offset by acquisition-driven expense growth and higher interest expense, so the quality of earnings and margin sustainability could be questioned.
Key entities
- companyCencora, Inc.
Reported fiscal 2026 Q3 results and raised fiscal 2026 adjusted diluted EPS guidance; also disclosed share repurchases and key segment drivers.
- acquisitionOneOncology
February 2026 acquisition cited as a driver of higher operating expenses and gross profit margin changes.
